The organizational structure of the proposed Clinical Trials Unit will comprise an Administrative Component and five Clinical Research Sites (Chatsworth, Umkomaas, Botha's Hill, Overport, Hlabisa) located in Durban, South Africa. The Administrative Component includes the CTU PI/Director, the CTU Co-PI/Deputy Director and two core staff groups;the Research Core and the Administrative Core. This Administrative Component will provide leadership to both stimulate and manage the Network research agenda, and ensure the highest scientific standards, ethical integrity and efficient fiscal and clinical operations within the CTU. The proposed Clinical Research Sites, staffed with highly competent teams, were selected based on available HIV/STI prevalence and incidence data, access to specific populations most affected by the HIV/AIDS epidemic, existing community partnerships, developed infrastructure, trained staff and established HIV prevention and treatment referral strategies for those identified as HIV positive at screening and those who seroconvert in prevention trials. These optimally configured Clinical Research Sites prominently positions the CTU to address the entire continuum of research needs within the HIV epidemic from prevention for HIV negative at-risk population, to treatment and care for HIV positive individuals. The CTU will have the flexibility and capability to conduct multiple studies at multiple Clinical Research Sites allowing for rapid response to the evolving epidemic, and ensuring optimal use of resources, both human and operational. Our research plan is to affiliate with both the HPTN and MTN Networks primarily due to our excellent track record in HIV prevention clinical trials. The Umkomaas, Overport and Botha's Hill Clinical Research Sites will participate in both Networks;while the Chatsworth and Hlabisa Clinical Research Sites will be dedicated to the MTN only. We intend to use a multidisciplinary approach to implement HIV prevention, treatment and behavioral research interventions, enhancing the CTUs ability to significantly contribute to addressing the HIV/AIDS epidemic locally, nationally and internationally. More importantly, we aim for research to benefit our communities by ensuring extensive community-wide HIV prevention education, home-based care/and lay counseling programs, at all Clinical Research Sites. ADMINISTRATIVE COMPONENT:

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI069422-06
Application #
8215938
Study Section
Special Emphasis Panel (ZAI1-MPM-A (M2))
Program Officer
Germuga, Donna E
Project Start
2007-03-01
Project End
2013-01-31
Budget Start
2012-02-01
Budget End
2013-01-31
Support Year
6
Fiscal Year
2012
Total Cost
$19,069,095
Indirect Cost
$1,600,450
Name
Medical Research Council of South Africa
Department
Type
DUNS #
635909489
City
Cape Town
State
Country
South Africa
Zip Code
Kasaro, Margaret P; Husnik, Marla J; Chi, Benjamin H et al. (2016) Impact of targeted counseling on reported vaginal hygiene practices and bacterial vaginosis: the HIV Prevention Trials Network 035 study. Int J STD AIDS :
van der Straten, Ariane; Brown, Elizabeth R; Marrazzo, Jeanne M et al. (2016) Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study. J Int AIDS Soc 19:20642
Moodley, Jeeva; Naidoo, Sarita; Moodley, Jayajothi et al. (2016) Sharing of Investigational Drug Among Participants in the Voice Trial. AIDS Behav 20:2709-2714
Baeten, Jared M; Palanee-Phillips, Thesla; Brown, Elizabeth R et al. (2016) Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med 375:2121-2132
Palanee-Phillips, Thesla; Schwartz, Katie; Brown, Elizabeth R et al. (2015) Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention. PLoS One 10:e0128857
Mensch, Barbara S; Gorbach, Pamina M; Kelly, Cliff et al. (2015) Characteristics Associated with HIV Drug Resistance Among Women Screening for an HIV Prevention Trial in KwaZulu-Natal, South Africa. AIDS Behav 19:2076-86
Marrazzo, Jeanne M; Ramjee, Gita; Richardson, Barbra A et al. (2015) Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med 372:509-18
Noguchi, Lisa M; Richardson, Barbra A; Baeten, Jared M et al. (2015) Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV 2:e279-87
Balkus, Jennifer E; Nair, Gonasagrie; Montgomery, Elizabeth T et al. (2015) Age-Disparate Partnerships and Risk of HIV-1 Acquisition Among South African Women Participating in the VOICE Trial. J Acquir Immune Defic Syndr 70:212-7
Balkus, Jennifer E; Richardson, Barbra A; Rabe, Lorna K et al. (2014) Bacterial vaginosis and the risk of trichomonas vaginalis acquisition among HIV-1-negative women. Sex Transm Dis 41:123-8

Showing the most recent 10 out of 12 publications